Prices are updated after-hours

Nasdaq 2021 - 02 - 25

Host Hotels

HST A | $18.705 0.62% 0.61% 3.9M

(0.0% 1d) (-11.5% 1m) (15.4% 1y) (0.0% 2d) (-0.2% 3d) (-4.4% 7d) (-51.41% volume)
Earnings Calendar: 2024-02-21
Market Cap: $ 13,160,838,000
http://www.hosthotels.com
Sec Filling | Patents | 175 employees

(US) Host Hotels & Resorts, Inc. is a self-managed and self-administered real estate investment trust, which engages in the management of luxury and upper-upscale hotels. It operates through the Hotel Ownership segment. Its properties are located in U.S., Brazil, Canada, and Mexico. The company was founded in 1927 and is headquartered in Bethesda, MD.

hotel brasil

add to watch list Paper trade email alert is off

Hurco Companies, Inc.

HURC | $19.02 -1.5% -1.52% 25K

Producer Manufacturing

(0.0% 1d) (-8.2% 1m) (-16.5% 1y) (0.0% 2d) (-1.4% 3d) (-1.7% 7d) (5.64% volume)
Earnings Calendar:
Market Cap: $ 123,744,748
http://www.hurco.com
Sec Filling | Patents | 785 employees

(US) Hurco Cos., Inc. is an international industrial technology company, which engages in the designing, manufacturing and selling of computerized machine tools. It also offers machine tool components, software options, control upgrades, accessories and replacement parts for its products, as well as customer service and training and applications support. The company was founded by Edward Humston and Gerald V. Roch in 1968 and is headquartered in Indianapolis, IN.

add to watch list Paper trade email alert is off

Huron Consulting Group Inc.

HURN 4 | $92.425 2.2% 2.15% 120K

Commercial Services

(0.0% 1d) (-3.2% 1m) (10.8% 1y) (0.0% 2d) (1.2% 3d) (1.3% 7d) (4.28% volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 1,707,496,143
http://www.huronconsultinggroup.com
Sec Filling | Patents | 3750 employees

Huron Consulting Group, Inc. engages in the provision of operational and financial consulting services. It operates through the following business segments: Healthcare, Business Advisory, and Education. The Healthcare segment provides advisory services in the areas of care transformation, financial and operational excellence, technology and analytics, and leadership development to national and regional hospitals and integrated health systems, academic medical centers, community hospitals, and medical groups. The Business Advisory segment offers services to large and middle market organizations, not-for-profit organizations, lending institutions, law firms, investment banks, and private equity firms. The Education segment includes consulting and technology solutions to higher education institutions and academic medical centers. The company was founded in March 2002 and is headquartered in Chicago, IL.

education urea profitable

add to watch list Paper trade email alert is off

ICF International, Inc.

ICFI | $140.185 1.52% 1.49% 47K

Commercial Services

(0.0% 1d) (-6.6% 1m) (28.3% 1y) (0.0% 2d) (0.1% 3d) (0.0% 7d) (-1.83% volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 2,623,614,985
http://www.icfi.com
Sec Filling | Patents | 7000 employees

(US) ICF International, Inc. engages in the provision of technology-based solutions and services to government and commercial clients. It serves the Energy, Environment, and Infrastructure; Health, Education, and Social Programs; Safety and Security; and Consumer and Financial markets. The company was founded in 1969 and is headquartered in Fairfax, VA.

energy education security

add to watch list Paper trade email alert is off

ICU Medical, Inc.

ICUI | $95.795 -1.14% -1.15% 180K

Health Technology

(0.0% 1d) (-2.8% 1m) (-47.1% 1y) (0.0% 2d) (-0.1% 3d) (-1.4% 7d) (29.72% volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 2,334,053,030
http://www.icumed.com
Sec Filling | Patents | 8000 employees

(United States) ICU Medical, Inc. engages in the development, manufacture, and sale of innovative medical devices used in vascular therapy and critical care applications. Its product portfolio includes intravenous smart pumps, sets, connectors, closed transfer devices for hazardous drugs, cardiac monitoring systems, IV solutions, IV smart pumps with pain management and safety software technology, dedicated and non-dedicated IV sets and needle-free connectors. The company was founded by George A. Lopez in 1984 and is headquartered in San Clemente, CA.

Drugs

Acetic Acid (Acetic Acid)
Aminosyn II (ISOLEUCINE, LEUCINE, LYSINE ACETATE, METHIONINE, PHENYLALANINE, THREONINE, TRYPTOPHAN, VALINE, ALANINE, ARGININE, ASPARTIC ACID, GLUTAMIC ACID, HISTIDINE, PROLINE, SERINE, N-ACETYLTYROSINE, and GLYCINE)
Aminosyn-PF (ISOLEUCINE, LEUCINE, LYSINE ACETATE, METHIONINE, PHENYLALANINE, THREONINE, TRYPTOPHAN, VALINE, ALANINE, ARGININE, ASPARTIC ACID, GLUTAMIC ACID, GLYCINE, HISTIDINE, PROLINE, SERINE, TAURINE, and TYROSINE)
Dextrose (dextrose)
Dextrose (dextrose monohydrate)
Dextrose and Sodium Chloride (DEXTROSE MONOHYDRATE and SODIUM CHLORIDE)
Glycine (GLYCINE)
Ionosol MB and Dextrose (DEXTROSE MONOHYDRATE, SODIUM LACTATE, POTASSIUM CHLORIDE, MAGNESIUM CHLORIDE, POTASSIUM PHOSPHATE, MONOBASIC, and SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE)
Lactated Ringers (SODIUM CHLORIDE, SODIUM LACTATE, POTASSIUM CHLORIDE, and CALCIUM CHLORIDE)
Lactated Ringers and Dextrose (SODIUM CHLORIDE, SODIUM LACTATE, POTASSIUM CHLORIDE, CALCIUM CHLORIDE, and DEXTROSE MONOHYDRATE)
Mannitol (MANNITOL)
NORMOSOL-M AND DEXTROSE (dextrose monohydrate, sodium chloride, potassium acetate, and magnesium acetate)
Normosol-R (SODIUM CHLORIDE, SODIUM ACETATE ANHYDROUS, SODIUM GLUCONATE, POTASSIUM CHLORIDE, AND MAGNESIUM CHLORIDE)
Normosol-R and Dextrose (Dextrose, Sodium Chloride, Sodium Acetate Anhydrous, Sodium Gluconate, Potassium Chloride, and Magnesium Chloride)
Physiosol (SODIUM CHLORIDE, SODIUM ACETATE ANHYDROUS, SODIUM GLUCONATE, POTASSIUM CHLORIDE, and MAGNESIUM CHLORIDE)
Potassium Chloride (POTASSIUM CHLORIDE)
Potassium Chloride in Dextrose (dextrose monohydrate and potassium chloride injection, solution)
Potassium Chloride in Dextrose and Sodium Chloride (DEXTROSE MONOHYDRATE, SODIUM CHLORIDE, and POTASSIUM CHLORIDE)
Potassium Chloride in Lactated Ringers and Dextrose (POTASSIUM CHLORIDE, SODIUM CHLORIDE, CALCIUM CHLORIDE, SODIUM LACTATE, and DEXTROSE MONOHYDRATE)
Potassium Chloride in Sodium Chloride (SODIUM CHLORIDE and POTASSIUM CHLORIDE)
Ringers (SODIUM CHLORIDE, POTASSIUM CHLORIDE, AND CALCIUM CHLORIDE)
Sodium Chloride (SODIUM CHLORIDE)
Sorbitol-Mannitol (SORBITOL and MANNITOL)
Sterile Water (water)
Sterile Water (WATER)

add to watch list Paper trade email alert is off

iHeartMedia, Inc.

IHRT 4 | $1.9 -1.55% -1.58% 950K

Consumer Services

(0.0% 1d) (-5.5% 1m) (-54.3% 1y) (0.0% 2d) (-2.6% 3d) (-10.0% 7d) (71.44% volume)
Earnings Calendar: 2024-02-29
Market Cap: $ 234,491,669
http://www.iheartmedia.com
Sec Filling | Patents | 11400 employees

iHeartMedia, Inc. engages in the provision of media and entertainment services. It operates through the following segments: Audio; Audio and Media Services; and Corporate and Other Reconciling Items. The Audio segment comprises of media and entertainment services via broadcast and digital delivery and also includes events and national syndication businesses. The Audio and Media Services segment consists of the other audio and media services, including the media representation business (Katz Media) and the provider of scheduling and broadcast software (RCS).The company was founded by L. Lowry Mays and B. J. McCombs in 1972 and is headquartered in San Antonio, TX.

audio

add to watch list Paper trade email alert is off

Immuron Limited

IMRN | $2.32 -5.31% -5.6% 26K

Health Technology

(0.0% 1d) (-9.8% 1m) (10.0% 1y) (0.0% 2d) (-4.1% 3d) (-10.8% 7d) (1917.45% volume)
Earnings Calendar:
Market Cap: $ 13,223,905
http://www.immuron.com
Sec Filling | Patents | 11 employees

(AU) Immuron Ltd. engages in the research and development of oral immunotherapy, and product sales which focuses on bovine-colostrum with antibodies of choice for the treatment and prevention of a range of infectious and immune modulated diseases. It operates through the following segments: Research and Development, and HyperImmune Products.The Research and Development segment involves the R&D projects performed in Australia, Israel, and United States. The HyperImmune Products segment comprises of Travelan, and Protectyn activities which occur in Australia, United States, and rest of the world. The company was founded on January 13, 1994 and is headquartered in Carlton, Australia.

antibody immunotherapy israel treatment

add to watch list Paper trade email alert is off

Independent Bank Corporation

IBCP | $24.29 3.01% 2.92% 55K

Finance

(0.0% 1d) (-1.5% 1m) (41.7% 1y) (0.0% 2d) (5.0% 3d) (5.3% 7d) (13.19% volume)
Earnings Calendar: 2024-01-25
Market Cap: $ 507,794,911
http://www.independentbank.com
Sec Filling | Patents | 994 employees

Independent Bank Corp. operates as a bank holding company. It provides financial services including commercial banking, mortgage lending, investments, and title services. The company was founded in 1864 and is headquartered in Ionia, MI.

msa

add to watch list Paper trade email alert is off

Innospec Inc.

IOSP | $122.37 1.28% 1.27% 67K

Process Industries

(0.0% 1d) (-4.2% 1m) (17.3% 1y) (0.0% 2d) (1.5% 3d) (0.4% 7d) (-12.4% volume)
Earnings Calendar: 2024-02-13
Market Cap: $ 3,052,741,384
http://www.innospecinc.com
Sec Filling | Patents | 2000 employees

Innospec, Inc. develops, manufactures, blends, markets and supplies fuel additives, oilfield chemicals, personal care, and other specialty chemicals. It operates through the following segments: Fuel Specialties, Performance Chemicals, Oilfield Services, and Octane Additives. The Fuel Specialties segment develops, manufactures, blends, markets, and supplies a range of specialty chemical products used as additives to a range of fuels. The Performance Chemicals segment provides technology-based solutions for customer's processes or products focused in the personal care, home care, agrochemical, and mining industries. The Oilfield Services segment develops and markets products to prevent loss of mud in drilling operations, chemical solutions for fracturing, stimulation and completion operations, and products for oil and gas production. The Octane Additives segment produces tetra ethyl lead, comprises sales of tetra ethyl lead for use in automotive gasoline and trading. The company was founded on May 22, 1998 and is headquartered in Englewood, CO.

bleeding automotive oil and gas mining

add to watch list Paper trade email alert is off

Innoviva, Inc.

INVA | $14.955 1.8% 1.77% 640K

Health Technology

(0.0% 1d) (-0.3% 1m) (24.8% 1y) (0.0% 2d) (3.2% 3d) (3.8% 7d) (22.17% volume)
Earnings Calendar: 2024-02-22
Market Cap: $ 945,564,765
http://www.inva.com
Sec Filling | Patents | 6 employees

(US) Innoviva, Inc. is engaged in the development, commercialization, and financial management of bio-pharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate; and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.

add to watch list Paper trade email alert is off

Inseego Corp.

INSG | $3.03 25.21% 20.13% 330K

Electronic Technology

(0.0% 1d) (-5.1% 1m) (356.5% 1y) (0.0% 2d) (29.3% 3d) (29.3% 7d) (1335.7% volume)
Earnings Calendar: 2024-02-21
Market Cap: $ 35,993,200
http://www.inseego.com
Sec Filling | Patents | 1007 employees

(US) Inseego Corp. engages in the design and development of fixed and mobile wireless solutions. It offers enterprise Internet of things, 4G long term evolution, and 5G services. The company was founded on April 26, 1996 and is headquartered in San Diego, CA.

5g

add to watch list Paper trade email alert is off

Insmed, Inc.

INSM | $24.4 -1.61% -1.64% 5.5M

Health Technology

(0.0% 1d) (-7.7% 1m) (33.5% 1y) (0.0% 2d) (-7.1% 3d) (-9.3% 7d) (356.9% volume)
Earnings Calendar: 2024-02-22
Market Cap: $ 3,624,747,295
http://www.insmed.com
Sec Filling | Patents | 435 employees

Insmed, Inc. is a biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Its first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Its earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, NJ.

hypertension fibrosis lungs treatment antibacterial profitable injection ycombinator

add to watch list Paper trade email alert is off

Intellia Therapeutics, Inc.

NTLA | $21.57 1.17% 1.16% 1.4M

Health Technology

(0.0% 1d) (-22.0% 1m) (-41.9% 1y) (1.2% 2d) (0.3% 3d) (-5.9% 7d) (27.22% volume)
Earnings Calendar: 2024-02-29
Market Cap: $ 2,080,180,775
http://www.intelliatx.com
Sec Filling | Patents | 270 employees

(US) Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

crispr genomic genome editing glass

add to watch list Paper trade email alert is off

Interactive Brokers Group, Inc.

IBKR 4 | $111.53 0.84% 0.83% 1M

Finance

(0.0% 1d) (1.5% 1m) (37.5% 1y) (0.0% 2d) (2.1% 3d) (2.2% 7d) (-59.39% volume)
Earnings Calendar: 2024-01-16
Market Cap: $ 11,940,660,661
http://www.interactivebrokers.com
Sec Filling | Patents | 1643 employees

(United States) Interactive Brokers Group, Inc. operates as an investment holding company, which engages in broker or dealer and proprietary trading businesses. It operates through the following segments: Electronic Brokerage and Corporate. The Electronic Brokerage segment is a direct market access broker, which serve the customers of both traditional brokers and prime brokers. The company was founded by Thomas Pechy Peterffy in 1977 and is headquartered in Greenwich, CT.

electronics

add to watch list Paper trade email alert is off

Intercept Pharmaceuticals, Inc.

ICPT | $19.0 -0.05% 4M

Health Technology

(0.0% 1d) (0.0% 1m) (-0.3% 1y) (0.0% 2d) (0.0% 3d) (0.1% 7d) (-100.0% volume)
Earnings Calendar: 2023-11-01
Market Cap: $ 794,693,354
http://www.interceptpharma.com
Sec Filling | Patents | 583 employees

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.

sclerosis liver liver disease treatment

add to watch list Paper trade email alert is off

International Bancshares Corporation

IBOC 4 | $54.4 3.54% 3.42% 450K

Finance

(0.0% 1d) (-2.8% 1m) (29.7% 1y) (0.0% 2d) (4.3% 3d) (3.3% 7d) (87.28% volume)
Earnings Calendar:
Market Cap: $ 3,381,951,821
http://www.ibc.com
Sec Filling | Patents | 3314 employees

International Bancshares Corp. is a financial holding company, which provides banking services for commercial, consumer, and international customers of South, Central, and Southeast Texas and the State of Oklahoma. It engages in the business of banking, including the acceptance of checking and savings deposits and the making of commercial, real estate, personal, home improvement, automobile and other installment and term loans. It also offers other related services, such as credit cards, travelers' checks, safety deposit, collection, notary public, escrow, drive-up and walk-up facilities and other customary banking services. The company was founded in 1979 and is headquartered in Laredo, TX.

automobile

add to watch list Paper trade email alert is off

Intra-Cellular Therapies Inc.

ITCI | $72.29 0.4% 0.4% 2.2M

Health Technology

(0.0% 1d) (5.8% 1m) (15.8% 1y) (-2.5% 2d) (-7.2% 3d) (10.3% 7d) (Infinity% volume)
Earnings Calendar: 2024-02-22
Market Cap: $ 6,998,191,837
http://www.intracellulartherapies.com
Sec Filling | Patents | 330 employees

Intra-Cellular Therapies, Inc. is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Its lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. The company also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease, and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates on August 29, 2013 and is headquartered in New York, NY.

neurodegenerative schizophrenia glass alzheimer heavy drug nervous system neuropsychiatric molecule drugs neurological msa treatment alzheimer’s

add to watch list Paper trade email alert is off

IntriCon Corporation

IIN | $24.24 0.04% 0.04%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (40.43% volume)
Earnings Calendar: 2022-08-08
Market Cap:
http://www.intricon.com
Sec Filling | Patents | 780 employees

Intricon Corp. engages in the design, development, engineering, manufacture, and distribution of miniature and micro-miniature body-worn devices. It operates through the Body-Worn Device and Hearing Health Direct-To-End Consumer segments. The Body-Worn Device segment comprises medical, hearing health, and professional audio markets. The Hearing Health Direct-To-End Consumer segment provides advanced hearing products such as ultra-miniature volume controls and trimmers, custom amplifiers, and custom, completed hearing instruments. The company was founded in 1930 and is headquartered in Arden Hills, MN.

audio

add to watch list Paper trade email alert is off

Intrusion Inc.

INTZ 4 | $1.695 0.89% 0.88% 180K

Electronic Technology

(0.0% 1d) (705.7% 1m) (40.5% 1y) (0.0% 2d) (-12.4% 3d) (-31.7% 7d) (-96.07% volume)
Earnings Calendar: 2024-03-07
Market Cap: $ 3,296,224
http://www.intrusion.com
Sec Filling | Patents | 32 employees

Intrusion, Inc. engages in the provision of network security solutions. It specializes in the development and marketing of entity identification, high speed data mining cybercrime and advanced persistent threat detection products. The company supports a range of customers including United States federal government entities, local government, banks, airlines, credit unions, and other financial institutions as well as hospitals, and other healthcare providers by providing products such as TraceCop for identity discovery and disclosure, and Savant for network data mining and advanced persistent threat detection. Intrusion was founded by T. Joe Head and G. Ward Paxton in September 1983 and is headquartered in Richardson, TX.

security mining

add to watch list Paper trade email alert is off

Inventiva S.A.

IVA | $3.35 -2.9% -2.99% 8.5K

Health Technology

(0.0% 1d) (-11.9% 1m) (25.2% 1y) (0.0% 2d) (3.4% 3d) (1.5% 7d) (-6.09% volume)
Earnings Calendar:
Market Cap: $ 175,798,580
http://www.inventivapharma.com
Sec Filling | Patents | 88 employees

(FR) Inventiva SA engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases. It owns an in-house drug-discovery platform that develops internal oncology and fibrosis discovery pipeline with approaches centred on transcription factors, epigenetics targets, and nuclear receptors. The company was founded by Pierre Broqua and Frédéric Cren on October 27, 2011 and is headquartered in Daix, France.

drug discovery fibrosis treatment housing nuclear

add to watch list Paper trade email alert is off